Eisai Co Ltd
TSE:4523
Net Margin
Eisai Co Ltd
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| JP |
|
Eisai Co Ltd
TSE:4523
|
1.1T JPY |
6%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
776.5B USD |
23%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
377.9B USD |
24%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
2.3T DKK |
35%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
214.5B CHF |
14%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
190.4B CHF |
24%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
170.3B GBP |
14%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
205.6B USD |
27%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
163.5B USD |
-126%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
139.5B USD |
13%
|
Eisai Co Ltd
Glance View
Eisai Co., Ltd., established in 1941, has emerged as a formidable player in the global pharmaceutical landscape, forging its reputation through a steadfast commitment to "human health care" (hhc). Rooted in Tokyo, the company orbits around the development of innovative treatments targeting neurology and oncology, positioning itself as a beacon of hope for patients worldwide. Eisai's journey is characterized by a persistent focus on medicinal breakthroughs in areas such as Alzheimer’s disease, liver cancer, and epilepsy—disease states that critically affect the quality of life but often have limited treatment options. Through its rigorous research and development efforts, the company crafts both small molecule drugs and biologics, distinguishing itself with flagship products like Aricept for Alzheimer's and Lenvima for cancer, both of which have cemented its reputation in the medical community and are vital streams of revenue. Eisai's business framework is intricately woven into a global tapestry of partnerships and collaborations, which amplifies its market reach and bolsters its financial performance. By strategically aligning with global pharmaceutical giants and leveraging robust patent portfolios, Eisai extends its innovative therapies to numerous markets. This strategic network allows it to not only enhance drug distribution and sales but also to engage in co-development, introducing shared stewardship in groundbreaking research. The company's financial structure is further reinforced through a diversified portfolio, inclusive of both branded prescription drugs and over-the-counter products, thus facilitating consistent cash flow and enabling ongoing investments in research. These deliberate steps underscore Eisai's pursuit of longevity in a fiercely competitive industry, ensuring it remains well-poised to continually adapt and thrive amidst evolving healthcare challenges.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Eisai Co Ltd's most recent financial statements, the company has Net Margin of 5.9%.
You don't have any saved screeners yet